NBTY “Tough Quarter” Caused By Vitamin E Sales, Stalled Market - Rudolph
This article was originally published in The Tan Sheet
Executive Summary
NBTY is predicting a rebound of the current stagnant supplement market as the baby boomer generation continues to enter the "vitamin age.
You may also be interested in...
Sales & Earnings In Brief
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...
Advil, ChapStick Drive Wyeth Consumer Growth, Offset Alavert Sales Drop
Growth in Advil,ChapStick andCentrum offset Alavert declines, leaving Wyeth Consumer Healthcare 2005 sales flat, the firm reported Jan. 31
Solgar Brand Leads First-Quarter NBTY Sales Growth
NBTY's recently-acquired Solgar vitamin brand continues to drive the firm's sales, the company reported in a first-quarter earnings statement Jan. 9